RecruitingPhase 3NCT05503264
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Studying Autoimmune encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Satralizumab(drug)
- Enrollment
- 152 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UC San Diego, La Jolla, California, United States
- Hoag Memorial Hospital, Newport Beach, California, United States
- UCSF- Multiple Sclerosis Centre, San Francisco, California, United States
- University of Colorado, Aurora, Colorado, United States
- Childrens National Health Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Brigham and Women's Hospital Department of Neurology, Boston, Massachusetts, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- NYU-Langone Medical Center, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- University Hospitals of Cleveland, Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Chugai Pharmaceutical
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05503264 on ClinicalTrials.govOther trials for Autoimmune encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07158229Long-term Impact of NMDAR Encephalitis, Level 3Hospices Civils de Lyon
- RECRUITINGNCT07477015Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune EncephalitisFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT06867991Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisThe First People's Hospital of Changzhou
- RECRUITINGNANCT06584045Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)Tongji Hospital
- RECRUITINGNCT07133113Medium-term Effects of Treatments in Autoimmune EncephalitisHospices Civils de Lyon
- RECRUITINGNCT06019975FDG-PET in the Diagnosis of Autoimmune EncephalitisUniversity of Milano Bicocca
- ACTIVE NOT RECRUITINGNCT07145502Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory SyndromesBiocells Medical
- RECRUITINGNANCT05198661Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis CollectionHospices Civils de Lyon